His scientific interests lie mostly in Immunology, Tuberculosis, Mycobacterium tuberculosis, Virology and Vaccination. All of his Immunology and Immune system and Cellular immunity investigations are sub-components of the entire Immunology study. His work in Immune system addresses issues such as Antigen, which are connected to fields such as Interferon gamma.
His study in Tuberculosis is interdisciplinary in nature, drawing from both Disease and Intensive care medicine. The Virology study combines topics in areas such as ESAT-6 and Immunity. His Vaccination study combines topics from a wide range of disciplines, such as Tuberculosis vaccines, Adjuvant and Immunization.
T. Mark Doherty mostly deals with Immunology, Tuberculosis, Mycobacterium tuberculosis, Virology and Vaccination. He has included themes like Latent tuberculosis and ESAT-6 in his Immunology study. His Tuberculosis research is multidisciplinary, incorporating elements of Disease, Incidence and Immunity.
His study looks at the intersection of Mycobacterium tuberculosis and topics like Asymptomatic with Sputum. T. Mark Doherty combines subjects such as Protein subunit, Subunit vaccines, Immunodominance and Clinical trial with his study of Virology. His research in Vaccination intersects with topics in Adjuvant, Mycobacterium bovis, Immunization and Gerontology.
T. Mark Doherty focuses on Vaccination, Gerontology, Tuberculosis, Internal medicine and Psychological intervention. His research integrates issues of Infectious disease, Disease, Antimicrobial and Immune system in his study of Vaccination. His Immune system study is related to the wider topic of Immunology.
Preventive healthcare, Influenza vaccine and Demographic change is closely connected to Population ageing in his research, which is encompassed under the umbrella topic of Gerontology. He interconnects Disease cluster, Incidence and Pneumonia in the investigation of issues within Tuberculosis. His Antigen research includes elements of Clinical trial, Pharmacovigilance and Virology.
T. Mark Doherty mainly investigates Vaccination, Gerontology, Psychological intervention, Infectious disease and Value. His Gerontology study combines topics in areas such as Translational research and Immunosenescence, Immune system. His studies deal with areas such as Obstetrics, Tetanus and Immunity, Passive immunity as well as Infectious disease.
Many of his Value research pursuits overlap with Immunization, Developed country and Vaccine-preventable diseases.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The success and failure of BCG - implications for a novel tuberculosis vaccine.
Peter Andersen;T. Mark Doherty.
Nature Reviews Microbiology (2005)
Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice
Robert S Wallis;Madhukar Pai;Madhukar Pai;Dick Menzies;Dick Menzies;T Mark Doherty.
The Lancet (2010)
Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients.
T. Mark Doherty;Abebech Demissie;Joseph Olobo;Dawit Wolday.
Journal of Clinical Microbiology (2002)
Exchanging ESAT6 with TB10.4 in an Ag85B Fusion Molecule-Based Tuberculosis Subunit Vaccine: Efficient Protection and ESAT6-Based Sensitive Monitoring of Vaccine Efficacy
Jes Dietrich;Claus Aagaard;Robert Leah;Anja W. Olsen.
Journal of Immunology (2005)
Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6.
Jan A.M. Langermans;T. Mark Doherty;Richard A.W. Vervenne;Tridia van der Laan.
Biomarkers for tuberculosis disease activity, cure, and relapse
Robert S. Wallis;T. Mark Doherty;Phillip Onyebujoh;Mahnaz Vahedi.
Lancet Infectious Diseases (2009)
Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers
Jaap T. van Dissel;Sandra M. Arend;Corine Prins;Peter Bang.
Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity.
Jes Dietrich;Claire Andersen;Rino Rappuoli;T. Mark Doherty.
Journal of Immunology (2006)
Recognition of Stage-Specific Mycobacterial Antigens Differentiates between Acute and Latent Infections with Mycobacterium tuberculosis
Abebech Demissie;Eliane M. S. Leyten;Markos Abebe;Liya Wassie.
Clinical and Vaccine Immunology (2006)
The prognosis of latent tuberculosis: can disease be predicted?
Peter Andersen;T. Mark Doherty;Madhukar Pai;Karin Weldingh.
Trends in Molecular Medicine (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: